News & Updates
Filter by Specialty:
Subcutaneous risperidone delays impending relapse in schizophrenia
Subcutaneous injection of risperidone QM or Q2M (TV-46000) has been shown to significantly delay impending relapse in patients with schizophrenia in the phase III RISE study.
Subcutaneous risperidone delays impending relapse in schizophrenia
10 Nov 2023
Sexual dysfunction affects >50 percent of patients with schizophrenia
Sexual dysfunction is highly prevalent in schizophrenia, affecting >50 percent of patients. Treatment of comorbid depression may be an effective strategy to improve sexual health, according to a meta-analysis.
Sexual dysfunction affects >50 percent of patients with schizophrenia
09 Nov 2023
Brexpiprazole improves agitation in Alzheimer’s dementia
A double-blind, placebo-controlled, randomized clinical trial reports significant improvement in agitation with brexpiprazole vs placebo among patients with Alzheimer’s dementia.
Brexpiprazole improves agitation in Alzheimer’s dementia
09 Nov 2023
IBS symptoms tied to depression, anxiety in NAFLD patients
Patients with nonalcoholic fatty liver disease (NAFLD) tend to have higher rates of irritable bowel syndrome (IBS) symptoms, depression, and anxiety, suggests a study.
IBS symptoms tied to depression, anxiety in NAFLD patients
04 Nov 2023
Esketamine outperforms quetiapine in head-to-head depression trial
In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.
Esketamine outperforms quetiapine in head-to-head depression trial
30 Oct 2023
Adult ADHD spells increased dementia risk
Adults with attention-deficit/hyperactivity disorder (ADHD) face a nearly threefold higher risk of dementia compared with those who do not have the neurodevelopmental condition, according to a study.